• Dr. Lebensburger is the Director, Pediatric Hematology Section in the Division of Pediatric Hematology Oncology. He has expertise in sickle cell disease and hemoglobinopathies, red cell disorders, ITP, bleeding disorders, blood clotting disorders, bone marrow failure syndromes, and general hematology.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Sex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemiaBlood Advances.  4:263-265. 2020
    2019 Effect of Sickle Cell Anemia Therapies on the Natural History of Growth and Puberty PatternsJournal of Pediatric Hematology/Oncology.  41:606-611. 2019
    2019 Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life 2019
    2019 Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathyAmerican Journal of Hematology.  94:417-423. 2019
    2019 Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic diseaseJournal of Allergy and Clinical Immunology.  143:1482-1495. 2019
    2019 American Society of Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and kidney diseaseBlood Advances.  3:3867-3897. 2019
    2019 End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settingsBlood Advances.  3:4002-4020. 2019
    2019 Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemiaAmerican Journal of Hematology.  94:E27-E29. 2019
    2019 Hyperfiltration predicts long-term renal outcomes in humanized sickle cell miceBlood Advances.  3:1460-1475. 2019
    2019 Roseamonas gilardii Bacteremia in a Patient with HbS╬▓0-thalassemia: Clinical Implications and Literature ReviewJournal of Pediatric Hematology/Oncology2019
    2018 Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis 2018
    2018 Red blood cell transfusion therapy for sickle cell patients with frequent painful events 2018
    2018 Outcomes of febrile events in pediatric patients with sickle cell anemia 2018
    2018 Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood 2018
    2018 Acute kidney injury during parvovirus B19-induced transient aplastic crisis in sickle cell diseaseAmerican Journal of Hematology.  93:E198-E200. 2018
    2018 Management of severe chronic pain with methadone in pediatric patients with sickle cell disease 2018
    2018 Outcomes in mild to moderate isolated thrombocytopeniaPediatrics.  142. 2018
    2018 Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preferenceBritish Journal of Haematology.  181:145-148. 2018
    2017 Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemiaPediatric Nephrology.  32:1565-1573. 2017
    2017 Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisisPediatric Nephrology.  32:1451-1456. 2017
    2017 Publication outcomes of abstracts from the American Society of Hematology Annual MeetingAmerican Journal of Hematology.  92:E81-E83. 2017
    2017 Cranial epidural hematomas: A case series and literature review of this rare complication associated with sickle cell disease 2017
    2017 Severe anemia early in life as a risk factor for sickle-cell kidney diseaseBlood.  129:385-387. 2017
    2017 Elective cholecystectomy reduces morbidity of cholelithiasis in pediatric sickle cell disease 2017
    2016 Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matricesRedox Biology.  9:167-177. 2016
    2016 Prevalence of acute kidney injury during pediatric admissions for acute chest syndromePediatric Nephrology.  31:1363-1368. 2016
    2016 Maintaining high level of care at satellite sickle cell clinicsJournal of Health Care for the Poor and Underserved.  27:280-292. 2016
    2015 Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemiaJournal of Blood Medicine.  6:285-290. 2015
    2015 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study 2015
    2015 Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell diseaseJournal of Neurosurgery: Pediatrics.  16:64-73. 2015
    2015 Exploring Adult Care Experiences and Barriers to Transition in Adult Patients with Sickle Cell Disease.International journal of hematology & therapy.  1. 2015
    2015 Patient-centered approach to designing sickle cell transition educationJournal of Pediatric Hematology/Oncology.  37:43-47. 2015
    2015 Systematic review of interventional sickle cell trials registered in ClinicalTrials.govClinical Trials.  12:575-583. 2015
    2015 Understanding and improving health education among first-time parents of infants with sickle cell anemia in alabama: A mixed methods approachJournal of Pediatric Hematology/Oncology.  37:35-42. 2015
    2014 Ferritin and LIC: Predicting liver injury in children with sickle cellJournal of Pediatric Gastroenterology and Nutrition.  58:387-390. 2014
    2014 Social skills and executive function among youth with sickle cell disease: A preliminary investigationJournal of Pediatric Psychology.  39:493-500. 2014
    2013 Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea 2013
    2013 Hydroxyurea treatment of children with hemoglobin SC disease 2013
    2012 Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study 2012
    2012 Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectinBlood.  119:1915-1921. 2012
    2012 Barriers in transition from pediatrics to adult medicine in sickle cell anemia.Journal of Blood Medicine.  3:105-112. 2012
    2011 Laboratory and clinical correlates for magnetic resonance imaging (MRI) abnormalities in pediatric sickle cell anemiaJournal of Child Neurology.  26:1260-1264. 2011
    2011 Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemiaAmerican Journal of Hematology.  86:430-432. 2011
    2011 What is the evidence for using hydroxyurea for secondary stroke prevention?Hematology online (ASH).  2011:440-442. 2011

    Research Overview

  • Dr. Lebensburger is an international expert in sickle cell kidney disease. He has received several prestigious research grants to study sickle cell kidney disease from the National Institutes of Health, American Society of Hematology, Pfizer ASPIRE Sickle Cell. He served on the American Society of Hematology Sickle Cell Guidelines Panel and the American Society of Hematology/Food and Drug Administration, Sickle Cell Trials Clinical Trial Endpoints Workshop. He is also focused on patient centered research including improving patient/parent education and transition of care. He is funded by the Patient Centered Outcomes Research Institute to study sickle cell transition of care. Finally, he has published numerous articles on other sickle cell complications including in stroke and pain. He was an investigator for several leading sickle cell trials.
    He also has a research interest in Immune Thrombocytopenia (ITP)serving as an investigator for the ITP Consortium of North America.
  • Principal Investigator On

  • Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2020 - 2024
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University 2015 - 2022
  • Comparative Effectiveness of Peer Mentoring versus Structured Education-Based Transition Programming for the Management of Care Transitions in Emerging Adults with Sickle Cell Disease.  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH 2018 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017 - 2020
  • Acute Kidney Injury During Sickle Cell Crisis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2020
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University 2016 - 2020
  • Chronobiology and Chronopharmacology to Prevent Sickle Cell Nephropathy  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2020
  • Chronobiology and Chronopharmacology to Prevent Sickle Cell Nephropathy  awarded by American Society of Hematology 2015 - 2018
  • Baby Hug Follow-Up Study II  awarded by University of Texas Southwestern Medical Center at Dallas 2013 - 2018
  • Patient Centered Research to Enhance Transition Education  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2014 - 2016
  • A Feasibility Trial Using Hydroxyurea for Secondary Prevention of Silent Cerebral Infracts in Children with Sickle Cell Disease  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2011 - 2015
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University 2013 - 2015
  • Private Grant  awarded by WYETH PHARMACEUTICALS, INC. 2010 - 2013
  • Investigator On

  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2025
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2019 - 2025
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015 - 2020
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Transforming Pediatric Oncology Healthcare Through Family Navigation  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2017 - 2019
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP 2015 - 2018
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2018
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2017
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2017
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee 2015 - 2016
  • CCOP Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2015
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP 2014
  • Pediatric Trial Network-Hydroxyuea/To 4  awarded by Duke University 2012 - 2014
  • COG Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2014
  • Private Grant  awarded by TERUMO BCT, INC. 2012 - 2013
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children  awarded by Johns Hopkins University 2011 - 2013
  • Private Grant  awarded by GLYCOMIMETICS, INC. 2010 - 2013
  • Baby HUG Follow-up Study II: Clinical Studies  awarded by University of Texas Southwestern Medical Center at Dallas 2012
  • Teaching Overview

  • Dr. Lebensburger teaches a wide array of courses in Hematology to Medical students, Pediatric residents, and pediatric Hematology Oncology Fellows. He currently mentors several recipients of career development grants.
    Dr. Lebensburger also serves as faculty at the American Society of Hematology Clinical Research Training Institute where he mentors young leaders in the field throughout the country.
  • Education And Training

  • Doctor of Osteopathy in Osteopathic Medicine / Osteopathy, Nova Southeastern University 2003
  • Arnold Palmer Children's Hospital, Internship 2004
  • Arnold Palmer Children's Hospital, Residency 2006
  • St. Jude Children's Research Hospital, Postdoctoral Fellowship 2009
  • Full Name

  • Jeffrey Lebensburger